Ubs Group Ag Roivant Sciences Ltd. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 6,797,203 shares of ROIV stock, worth $72.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

6,797,203

Previous 5,289,774 28.5%

Holding current value

$72.2 Million

Previous $62.6 Million 9.6%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$10.09 - $12.08 $15.2 Million - $18.2 Million	1,507,429 Added 28.5%	6,797,203 $68.6 Million
Q4 2024 Feb 14, 2025	BUY	$11.16 - $12.71 $53.3 Million - $60.7 Million	4,779,042 Added 935.72%	5,289,774 $62.6 Million
Q3 2024 Nov 14, 2024	BUY	$10.17 - $12.5 $166,615 - $204,787	16,383 Added 3.31%	510,732 $5.89 Million
Q2 2024 Aug 13, 2024	SELL	$10.36 - $11.74 $448,049 - $507,731	-43,248 Reduced 8.04%	494,349 $5.23 Million
Q1 2024 May 13, 2024	BUY	$9.87 - $11.8 $3 Million - $3.58 Million	303,708 Added 129.85%	537,597 $5.67 Million
Q4 2023 Feb 09, 2024	BUY	$8.38 - $11.58 $29,690 - $41,027	3,543 Added 1.54%	233,889 $2.63 Million
Q3 2023 Nov 09, 2023	SELL	$9.76 - $13.19 $1.45 Million - $1.96 Million	-148,704 Reduced 39.23%	230,346 $2.69 Million
Q2 2023 Aug 11, 2023	BUY	$7.09 - $10.08 $2.63 Million - $3.74 Million	371,480 Added 4907.27%	379,050 $3.82 Million
Q1 2023 May 12, 2023	SELL	$6.92 - $9.98 $1.06 Million - $1.53 Million	-153,442 Reduced 95.3%	7,570 $55,000
Q4 2022 Feb 08, 2023	BUY	$3.36 - $7.99 $541,000 - $1.29 Million	161,012 New	161,012 $1.29 Million

Others Institutions Holding ROIV

# of Institutions

331

Shares Held

496M

Call Options Held

3.67M

Put Options Held

754K

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $7.48B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account